(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 May 2012 (10.05.2012)

PCT

(10) International Publication Number
WO 2012/059873 A2

(51) International Patent Classification:
A61K 47/48 (2006.01)

(21) International Application Number:
PCT/IB2011/054874

(22) International Filing Date:
2 November 2011 (02.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/410,715 5 November 2010 (05.11.2010) US

(71) Applicants *(for all designated States except US)*: **COVX TECHNOLOGIES IRELAND, LTD.** [IE/IE]; Pottery Road Dun Laoghaire, County Dublin (IE). **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ISHINO, Tetsuya** [JP/US]; Pfizer Global Research and Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **PALANKI, Moorthy Sitharamaiah Suriyanarayana** [US/US]; CovX Research LLC 9381 Judicial Drive, Suite 200, San Diego, California 92121 (US). **VIOLAND, Bernard Norman** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Village Parkway, Chesterfield, Missouri 63017 (US). **DAS, Tapan, Kanti** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **HODGE, Tamara, Shafer** [US/US]; 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **LEVIN, Nancy, Jane** [US/US]; CovX Research LLC, 9381 Judicial Drive, Suite 200, San Diego, CA 92121 (US). **PARSONS, Erin, Kristen** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US).

(74) Agent: **BENSON, Gregg C.**; Pfizer Inc. Eastern Point Road MS9114, Groton, Connecticut 06340 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTI-DIABETIC COMPOUNDS

(57) Abstract: The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

WO 2012/059873 A2